B-Cell Composition in the Blood and Cerebrospinal Fluid of Multiple Sclerosis Patients Treated With Dimethyl Fumarate

Multiple Sclerosis and Related Disorders - United States
doi 10.1016/j.msard.2018.08.032
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Nonfatal PML in a Patient With Multiple Sclerosis Treated With Dimethyl Fumarate

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2016English

Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis

Prescriber
Pharmacology
2014English

Dimethyl Fumarate Treatment Alters NK Cell Function in Multiple Sclerosis

European Journal of Immunology
AllergyImmunology
2017English

Cerebrospinal Fluid and Serum Uric Acid Levels in Patients With Multiple Sclerosis

Clinical Chemistry and Laboratory Medicine
BiochemistryMedicineClinical Biochemistry
2009English

Quantitative Proteomic Analysis of the Cerebrospinal Fluid of Patients With Multiple Sclerosis

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2009English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

HDL-cholesterol Elevation Associated With Fingolimod and Dimethyl Fumarate Therapies in Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Dimethyl Fumarate in the Management of Multiple Sclerosis: Appropriate Patient Selection and Special Considerations

Therapeutics and Clinical Risk Management
2016English

Comparison of Antibodies With Amylase Activity From Cerebrospinal Fluid and Serum of Patients With Multiple Sclerosis

PLoS ONE
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy